Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Long-term Potentiation01:35

Long-term Potentiation

58.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
58.9K
Long-term Potentiation01:25

Long-term Potentiation

3.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.7K
Long-term Depression01:03

Long-term Depression

3.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Fructose-2,6-bisphosphate restores TDP-43 pathology-driven genome repair deficiency in motor neuron diseases.

Communications biology·2026
Same author

PLD1-Dependent Regulation of Synaptic Integrity: Implications for Cognitive Resilience and Alzheimer's Disease Pathogenesis.

bioRxiv : the preprint server for biology·2026
Same author

Regional correlates of tau pathology and synaptic function in primary age-related tauopathy.

Journal of Alzheimer's disease : JAD·2026
Same author

From Pathology to Materials Science and Engineering: Harnessing the Amyloid State for Biotechnological Applications.

ACS applied materials & interfaces·2025
Same author

Exosome-Mediated Delivery of a PLD1 Modulator Overcomes Bioavailability Hurdles to Target Synaptopathy in Neurodegenerative Diseases.

Pharmaceutical research·2025
Same author

A brain-derived tau oligomer polymorph is associated with cognitive resilience to Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

相关实验视频

Updated: Feb 24, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K

在前性痴呆症中探索PLD1-tau相互作用

Chandramouli Natarajan, Shaneilahi M Budhwani, Sravan Gopalkrishna Shetty Sreenivasamurthy

    bioRxiv : the preprint server for biology
    |February 23, 2026
    PubMed
    概括

    脂酶D1 (PLD1) 在前性痴呆症 (FTD) 中有助于突触缺陷和病理. 准PLD1可能为FTD和相关病症提供治疗策略.

    科学领域:

    • 神经科学是一个神经科学.
    • 生物化学 生物化学

    背景情况:

    • 前性痴呆 (FTD) 是年轻发病痴呆的主要原因,其特点是认知能力下降和前性缩.
    • 病症在近40%的FTD病例中存在,但驱动聚和突触功能障碍的分子机制尚未完全理解.

    研究的目的:

    • 调查脂酶D1 (PLD1) 在FTD相关的病理和突触缺陷中的作用.
    • 探索PLD1对FTD突触功能障碍的贡献,考虑到它对阿尔茨海默病和肌缩性侧面硬化症的影响.

    主要方法:

    • 从FTD患者和对照人群中对死后叶和额叶皮层的分析.
    • 利用光辅助单突触体长期强化 (FASS-LTP),免疫光,近距离结合试验 (PLA) 和PLD1-相互作用蛋白质组学.
    • 检查了PLD1的表达,与tau物种和突触标记物的同定位,以及不同细胞组中的蛋白质组变化.

    主要成果:

    • 在FTD大脑中,Glutamatergic强度降低,在特定的皮质区域增加PLD1表达.
    • PLD1与病理性tau物种 (总,高酸化和乙化tau寡合体) 和突触标记物有显著的共同局部化.
    • 蛋白质组分析揭示了分区特异性变化,包括突触蛋白质稳定性受损和星参与度增加,蛋白质从突触再分配到细胞质中.

    结论:

    更多相关视频

    Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
    10:38

    Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases

    Published on: December 22, 2023

    1.1K
    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    18.4K

    相关实验视频

    Last Updated: Feb 24, 2026

    In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
    09:22

    In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

    Published on: January 2, 2015

    19.1K
    Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
    10:38

    Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases

    Published on: December 22, 2023

    1.1K
    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    18.4K
    • 在FTD中,PLD1是突触功能障碍和病理的关键调解者.
    • PLD1通过星细胞激活作用,并破坏突触蛋白质稳定,导致神经退行.
    • PLD1减弱为FTD和相关病症恢复突触完整性提供了潜在的治疗标.